SPI Pharma, Inc. and Inimmune, Corp. Launch Partnership to Commercialize Advanced Adjuvant Systems

Wilmington, Delaware, October 22, 2024 – SPI Pharma, Inc., a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, finalized their partnership to bring two adjuvant systems to market. The partners will launch these novel adjuvant systems at the […]

Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery

Cambridge, Mass, September 13, 2024 – Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico’s proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics. Chemistry42, a multi-agent reinforcement learning system designed […]

Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist

MISSOULA, Montana, July 24, 2024 – Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with advanced solid tumors. This is an open-label, multiple-ascending dose, two-part dose […]

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

MISSOULA, Montana, July 16, 2024 – SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. […]

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

MISSOULA, Montana, January 8, 2024 – Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its […]

Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023

MISSOULA, MT, December 1, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel cancer immunotherapies and vaccine adjuvants and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a presentation at the upcoming MedInvest Oncology Conference in Palo Alto California December 5-6th. The event brings […]

Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA

Missoula, MT, November 30, 2023 – Inimmune, a leading clinical stage biotech company focused on thedevelopment of novel vaccines and immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at World Vaccine Congress (West Coast). Innovative vaccine adjuvants and delivery technologies have demonstrated great progress for treatment and […]

UM and Inimmune Receive $12.3 M NIH Contract to Advance New Adjuvant for Vaccines Targeting Bacterial and Fungal Infections

Contact: Jay Evans, research professor, UM Center for Translational Medicine director, 406-381-0573, jay.evans@umontana.edu. UM Leads $12.3M Contract to Advance TB VaccineUM News Service MISSOULA, Montana, October, 29, 2023 – The National Institutes of Health recently awarded a $12.3 million contract to the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosis […]

Inimmune Collaborates with Boston Children’s Hospital to Develop Novel Adjuvants

MISSOULA, Montana, October, 24, 2023 – Inimmune Corporation, a clinical-stage biotechnology company focused on creating and developing innovative immunotherapeutics, announced that it has entered a research collaboration with Boston Children’s Hospital (BCH) to develop novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a […]